Pasithea Therapeutics Corp. (KTTA) Reports Durable Stable Disease, Clean Safety in PAS-004 Phase 1

Pasithea Therapeutics (KTTA) reported Phase 1 trial data for PAS-004, an oral MEK inhibitor, showing stable disease in advanced solid tumor patients. Four patients remained on treatment for over 300 days, with two over 500 days. No dose-limiting toxicities were observed. The data was presented at ESMO Congress 2026.

Pasithea Therapeutics (KTTA) reported positive data from its Phase 1 trial of PAS-004, showing prolonged stable disease in four advanced cancer patients, including two on treatment for over 500 days. The drug demonstrated a favorable safety profile with no serious adverse events and a long half-life supporting chronic dosing. Data was presented at ESMO Congress 2026.

Pasithea Therapeutics (KTTA) said the U.S. FDA granted Orphan Drug Designation to PAS-004 for amyotrophic lateral sclerosis (ALS). The company said PAS-004 is a macrocyclic MEK inhibitor and is in Phase 1 trials in advanced cancer and Phase 1/1b trials in NF1-associated plexiform neurofibromas. Orphan status can bring tax credits, fee exemptions, and up to seven years’ exclusivity after approval.

Bristol Myers Squibb (BMY) shared Phase 1 data for zolacabtagene autoleucel (zola-cel) in MS patients, showing promising results. Separately, BMY expanded its AI collaboration with Tempus (TEM) through 2031. BMY stock is down 2.30%, TEM up 1.54%.

Bristol Myers Squibb (BMY) reported interim Phase 1 Breakfree-2 study results for its CAR T-cell therapy zolacabtagene autoleucel in 66 multiple sclerosis patients. 92% of progressive MS patients showed stable or improved disability. Safety issues included cytokine release syndrome in 42.4% of patients. BMY stock is down 2.26% at $61.56.

Guggenheim kept a Buy rating on AppFolio, setting a $239 price target, a 10% upside from its Oct 22 close. The firm cited strong growth potential in real estate software and positive valuation adjustments.